Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2024-11-06 00:00:00 ET · period of report 2024-11-04 · accession 0000950170-24-122640 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-06 | 2024-11-04 | AMLX | Klee Justin B. | Co-CEO, Dir | M - OptEx | $1.57 | +63.7K | 3.18M | +2% | +$100.0K |
| D | 2024-11-06 | 2024-11-04 | AMLX | Klee Justin B. | Co-CEO, Dir | M - OptEx | $0.00 | -63.7K | 36.3K | -64% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-04 | M | A | 63,690 | $1.57 | 3,184,259 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2024-11-04 | M | D | 63,690 | $0.00 | 36,310 | D | $1.57 · — to 2025-02-26 | 63,690 Common Stock | (F1) This option is fully vested and exercisable. |